The dasatinib senolytic protocol uses the same 100 mg dose as CML treatment but dramatically reduces total exposure by limiting treatment to 2–3 days per quarter (vs 365 days/year for CML). This intermittent approach maintains sufficient plasma drug levels to trigger senolytic apoptosis during the burst window while avoiding the chronic exposure that drives pleural effusion and peripheral neuropathy.

What happens if I take dasatinib more frequently than quarterly?

More frequent dosing increases total cumulative exposure and side effect risk without clear additional senolytic benefit. Monthly D+Q is used in some protocols for older individuals with high disease burden, but requires closer physician monitoring.

Should I take dasatinib in the morning or evening?

No clinical evidence favors a specific timing. Taking with food reduces GI side effects. Morning dosing may align with cortisol peaks that influence cellular stress responses, but this is speculative. Consistency in timing across the protocol days is more important than specific time of day.